Japan Pharma: Upcoming Catalysts & Event Driven Trading Ideas
Takeda Pharmaceutical Co Ltd (4502 JP), Shionogi & Co Ltd (4507 JP), Nippon Shinyaku Co Ltd (4516 JP) , Sumitomo Dainippon Pharma Co (4506 JP),...
316 Views
Symbio Pharma (4582 JP) -Â Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
259 Views
Japan Pharmaceutical - Sector Overview
Core coverage – relative valuations Takeda Pharmaceutical Co Ltd (4502 JP) (NB: Pre-Shire announcement | Pro-Forma analysis to be published...
329 Views
Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017
Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...
319 Views
New Stem Cell Treatment for Parkinsons Positive for Catalent and Eisai
A pioneering new stem cell treatment with the 'potential to cure Parkinson's disease' has been crafted by researchers. In trials on laboratory...
280 Views